Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
August 30, 2023 08:30 ET
|
Denali Therapeutics Inc.
Additional biomarker data up to two years of treatment continue to demonstrate rapid and sustained normalization of CSF heparan sulfate to normal healthy levels and improvement in lysosomal function...
Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™
February 05, 2021 09:00 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
InvestorBrandNetwork Announces Gamechangers LIVE Interview with CNS Pharmaceuticals Inc. Chairman & CEO John Climaco
December 09, 2020 09:00 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Dec. 09, 2020 (GLOBE NEWSWIRE) -- via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV:IDS (DNL310) in Hunter Syndrome (MPS II)
November 10, 2020 07:30 ET
|
Denali Therapeutics Inc.
After four weekly intravenous doses of DNL310, a 76% mean reduction in CSF GAG levels (heparan sulfate) from baseline was observed, with normal healthy levels being achieved in four of five...
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
May 27, 2020 16:30 ET
|
Denali Therapeutics Inc.
Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with DNL310 (ETV:IDS), the...
Voyager Therapeutics Announces Additional Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting
May 18, 2018 18:30 ET
|
Voyager Therapeutics, Inc.
Voyager’s gene therapy vector for Friedreich’s ataxia prevents central and peripheral disease progression in preclinical model out to one year after a single administration Durable safety data...
Voyager Therapeutics Announces Publication from the California Institute of Technology of a Second-Generation Gene Therapy Capsid Demonstrating Further Enhanced Gene Transfer to the Brain
July 17, 2017 07:04 ET
|
Voyager Therapeutics
A single, intravenous administration of a novel AAV capsid provided up to 100-fold increase in gene transfer to the central nervous system in a preclinical model compared to the historical standard...